{"id":"pbk-m2101-2-day","safety":{"commonSideEffects":[{"rate":null,"effect":"Unknown"}]},"_chembl":{"chemblId":"CHEMBL3348923","moleculeType":"Small molecule","molecularWeight":"506.30"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The exact mechanism of action is not well understood, but it is believed to work through a specific pathway.","oneSentence":"PBK_M2101 2-Day is a small molecule that targets the molecular target.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:50:57.772Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Phase 3 clinical trial for a specific indication"}]},"trialDetails":[{"nctId":"NCT05923918","phase":"PHASE3","title":"A Study to Evaluate Safety and Efficacy of PBK_M2101","status":"UNKNOWN","sponsor":"Pharmbio Korea Co., Ltd.","startDate":"2023-06","conditions":"Intestinal Disease, Colonic Diseases, Gastrointestinal Disease","enrollment":246}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"PBK_M2101 2-Day","genericName":"PBK_M2101 2-Day","companyName":"Pharmbio Korea Co., Ltd.","companyId":"pharmbio-korea-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PBK_M2101 2-Day is a small molecule that targets the molecular target. Used for Phase 3 clinical trial for a specific indication.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}